About Levosimendan Injection 12.5mg
Introducing the new release: Levosimendan Injection 12.5mg, a brilliant and customizable solution for acute decompensated severe chronic heart failure. With its valiant inotropic support and redoubtable cardiovascular efficacy, this prescription-only injectable offers rapid therapeutic action when administered intravenously under medical supervision. Manufactured strictly under GMP guidelines in India, each vial contains a precise 12.5 mg/5 ml dose of Levosimendan. Clear to yellowish in appearance, it remains stable for 2 years. Take advantage of this innovative cardiac stimulant, expertly formulated for hospital use in adult patients.
Application and Usage: Targeted Intravenous Therapy
Levosimendan Injection 12.5mg is designed for intravenous administration, providing targeted therapy directly into the bloodstream for rapid onset. Intended strictly for hospital settings, its use type is prescription-based and supervised by qualified healthcare professionals. This inotropic agent is primarily used for acute situations in heart failure patients, ensuring effective and controlled intervention. Always follow the physician's exact instructions for dosing and administration to maximize therapeutic benefits while minimizing risks.
Export Marked Packaging and Payment Flexibility
Levosimendan Injection 12.5mg comes packaged in vials, one per box, ensuring product integrity and convenience. Our export market standards mean the product is supplied with secure packaging and Stock Ready for prompt dispatch. Transportation is optimized for safety, adhering to proper storage conditions. Payment terms are flexible, accommodating various transaction methods to suit suppliers and traders. For new clients, samples are available upon request to evaluate quality and compliance with global standards.
FAQ's of Levosimendan Injection 12.5mg:
Q: How should Levosimendan Injection 12.5mg be administered?
A: The injection should be given intravenously by a qualified healthcare professional in a hospital setting, following the dosage and guidelines prescribed by the physician.
Q: What are the primary indications for using Levosimendan Injection 12.5mg?
A: It is recommended for adults suffering from acute decompensated severe chronic heart failure who require inotropic support for improved cardiac performance.
Q: When is it appropriate to initiate treatment with Levosimendan Injection?
A: Treatment is initiated when an adult patient with chronic heart failure experiences acute decompensation and requires rapid cardiovascular intervention, under strict medical supervision.
Q: Where is this product manufactured and is regulatory approval assured?
A: Levosimendan Injection 12.5mg is manufactured in India with full compliance to current GMP guidelines, ensuring quality and regulatory standards are met.
Q: What are the packaging and storage instructions for Levosimendan Injection?
A: Each vial contains 12.5 mg in 5 ml, packed individually per box. Store the product below 25C and protect from light to maintain its efficacy throughout its 2-year shelf life.